New Technologies for Influenza Vaccines

Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vac...

Full description

Saved in:
Bibliographic Details
Published in:Microorganisms (Basel) 2020-11, Vol.8 (11), p.1745
Main Authors: Rockman, Steven, Laurie, Karen L., Parkes, Simone, Wheatley, Adam, Barr, Ian G.
Format: Article
Language:English
Subjects:
cell-based influenza vaccines
cell-culture
egg-based influenza vaccines
influenza
Review
universal vaccine
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms8111745